JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Search

Certara Inc

Închisă

SectorSănătate

5.99 -5.52

Rezumat

Modificarea prețului

24h

Curent

Minim

5.86

Maxim

6.35

Indicatori cheie

By Trading Economics

Venit

-7.4M

-5.9M

Vânzări

-968K

104M

P/E

Medie Sector

100.714

60.328

Marjă de profit

-5.688

Angajați

1,515

EBITDA

8.6M

32M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+33.23% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-49M

985M

Deschiderea anterioară

11.51

Închiderea anterioară

5.99

Sentimentul știrilor

By Acuity

38%

62%

139 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Certara Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2026, 00:00 UTC

Câștiguri

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 apr. 2026, 00:00 UTC

Câștiguri

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 apr. 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 apr. 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 apr. 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 apr. 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 apr. 2026, 23:13 UTC

Achiziții, Fuziuni, Preluări

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 apr. 2026, 22:33 UTC

Câștiguri

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 apr. 2026, 22:17 UTC

Câștiguri

PLS Executed Offtake Agreement With Ronbay

23 apr. 2026, 22:17 UTC

Câștiguri

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 apr. 2026, 22:16 UTC

Câștiguri

PLS Commences Commissioning of Midstream Demonstration Plant

23 apr. 2026, 22:15 UTC

Câștiguri

PLS Group Reaffirms FY26 Guidance for All Metrics

23 apr. 2026, 22:14 UTC

Câștiguri

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 apr. 2026, 22:14 UTC

Câștiguri

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 apr. 2026, 22:13 UTC

Câștiguri

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 apr. 2026, 22:12 UTC

Câștiguri

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 apr. 2026, 22:12 UTC

Câștiguri

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 apr. 2026, 22:11 UTC

Câștiguri

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 apr. 2026, 22:10 UTC

Câștiguri

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 apr. 2026, 22:09 UTC

Câștiguri

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 apr. 2026, 22:08 UTC

Câștiguri

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 apr. 2026, 22:04 UTC

Câștiguri

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 apr. 2026, 21:56 UTC

Market Talk
Câștiguri

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 apr. 2026, 21:48 UTC

Achiziții, Fuziuni, Preluări

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 apr. 2026, 21:27 UTC

Câștiguri

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 apr. 2026, 21:25 UTC

Câștiguri

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 apr. 2026, 21:24 UTC

Câștiguri

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 apr. 2026, 21:24 UTC

Câștiguri

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 apr. 2026, 21:21 UTC

Câștiguri

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 apr. 2026, 21:21 UTC

Câștiguri

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Comparație

Modificare preț

Certara Inc Așteptări

Obiectiv de preț

By TipRanks

33.23% sus

Prognoză pe 12 luni

Medie 8.5 USD  33.23%

Maxim 10 USD

Minim 7 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCertara Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

3

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

11.27 / 12.79Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

139 / 348 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat